{
  "source": "PA-Notification-Xtandi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1117-15\nProgram Prior Authorization/Notification\nMedication Xtandi® (enzalutamide)\nP&T Approval Date 11/2012, 7/2013, 8/2013, 11/2014, 11/2015, 9/2016, 9/2017, 5/2018,\n8/2018, 9/2019, 3/2020, 3/2021, 3/2022, 3/2023, 3/2024, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nXtandi® (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of patients\nwith castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer\n(mCSPC), and non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical\nrecurrence at high risk for metastasis (high-risk BCR).\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Xtandi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Prostate Cancer\n1. Initial Authorization\na. Xtandi will be approved based on both of the following criteria:\n(1) Diagnosis of prostate cancer\n-AND-\n(2) One of the following:\n(a) Both of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\ni. Disease is castration-resistant\nii. One of the following:\n• Used in combination with a gonadotropin-releasing hormone (GnRH)\nanalog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar\n(triptorelin), Vantas (histrelin), Firmagon (degarelix)]\n• Patient has had bilateral orchiectomy\n-OR-\n(b) Both of the following:\ni. Disease is metastatic castration-sensitive",
    "dex (goserelin), Trelstar\n(triptorelin), Vantas (histrelin), Firmagon (degarelix)]\n• Patient has had bilateral orchiectomy\n-OR-\n(b) Both of the following:\ni. Disease is metastatic castration-sensitive\nii. One of the following:\n• Used in combination with a gonadotropin-releasing hormone (GnRH)\nanalog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar\n(triptorelin), Vantas (histrelin), Firmagon (degarelix)]\n• Patient has had bilateral orchiectomy\n-OR-\n(c) Disease is non-metastatic castration-sensitive with biochemical recurrence at\nhigh risk for metastasis\nAuthorization will be issued for 12 months.\n2. Reauthorization Criteria\na. Xtandi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Xtandi therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Xtandi [package insert]. Northbrook, IL: Astellas Pharma US, Inc. March 2025.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed April 28, 2025.\nProgram Prior ",
    "ma US, Inc. March 2025.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed April 28, 2025.\nProgram Prior Authorization/Notification - Xtandi (enzalutamide)\nChange Control\n11/2014 Annual review. Added ‘relapsed’ to prostate cancer criteria. Updated\nbackground & references.\n11/2015 Annual review. Revised prostate cancer criteria. Updated background &\nreferences.\n9/2016 Annual review. Updated references\n9/2017 Annual review. Updated background and criteria to include NCCN\nrecommendation as initial androgen deprivation therapy for prostate cancer\nin combination with a GnRH agonist. Updated references.\n5/2018 Updated background and criteria to remove criteria for use as initial\nandrogen deprivation therapy as no longer recommended by NCCN.\n8/2018 Updated background and criteria with to align with new indication in non-\nmetastatic setting. Updated criteria to include requirement to use in\ncombination with GnRH analog or bilateral orchiectomy as per label.\n9/2019 Annual review with no changes to coverage criteria. Updated reference.\nAdded general NCCN recommended review criteria.\n3/2020 Updated background and criteria to include new labeled indication for\nmetastatic castration-sensitive prostate cancer.\n3/2021 Annual review. No changes to coverage criteria. Updated references.\n3/2022 Annual review. No changes to coverage criteria. Updated references.\n3/2023 Annual review with no change to coverage criteria. Updated references.\nAdded state mandate footnote.\n3/2024 Annual review. Updated background and criteria with expanded indication\nin non-metastatic castration-sensitive setting. Updated references.\n6/2024 Updated criteria to reflect that for non-metastatic castration-sensitive\nprostate cancer concomitant use with GnRH is not required.\n6/2025 Annual review with no change to coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}